Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.54 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.51 |
| ▸ | PLTP | P55058 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2489832 | 0.92 | TRPV4 (0.57) | ADORA1ADORA3DGAT1PLTPPTGDR2 | |
| SCHEMBL2487641 | 0.91 | DGAT1 (0.49) | ADORA1ADORA3DGAT1PLTPADORA2A | |
| SCHEMBL2487360 | 0.91 | DGAT1 (0.63) | ADORA1ADORA3DGAT1PLTPADORA2A | |
| SCHEMBL2490614 | 0.90 | NPC1 (0.51) | ADORA1ADORA3DGAT1PLTPMEN1 | |
| SCHEMBL2316605 | 0.89 | ADORA1 (0.52) | ADORA1ADORA3DGAT1PLTPADORA2A | |
| SCHEMBL2487506 | 0.88 | PLTP (0.52) | ADORA1DGAT1PLTPADORA2APTGDR2 | |
| SCHEMBL2315021 | 0.88 | RORC (0.58) | ADORA1ADORA3DGAT1PLTPPTGDR2 | |
| SCHEMBL2484995 | 0.88 | PLTP (0.51) | ADORA1DGAT1PLTPADORA2APTGDR2 | |
| SCHEMBL2485677 | 0.88 | PLTP (0.51) | ADORA1ADORA3DGAT1PLTPADORA2A | |
| SCHEMBL2488081 | 0.87 | PLTP (0.50) | ADORA1ADORA3DGAT1PLTPADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | ADORA1 2075/4885ADORA3 2247/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.